Commercially bioavailable proprietary technologies and their marketed products.

In this review, we discuss the methodologies and platform technologies for enhancing the oral bioavailability of poorly soluble drugs. We also highlight the mechanisms of formulation technologies for improving desired physicochemical attributes of active substances. We focus on various commercial technologies, along with marketed products, and identify proprietary technologies protected by patents. We also discuss nonpropriety technologies, such as mesoporous silica, cyclodextrin complexation and solid dispersions. In addition, we highlight the factors affecting drug absorption and/or bioavailability, the methodologies available to prepare bioavailability-enhanced products, stability issues and examples of technology implementation.

[1]  V. Kadam,et al.  DRUG NANOCRYSTALS: NOVEL TECHNIQUE FOR DELIVERY OF POORLY SOLUBLE DRUGS , 2011 .

[2]  Vesa-Pekka Lehto,et al.  Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. , 2010, Molecular pharmaceutics.

[3]  Claus-Michael Lehr,et al.  Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  H. Okamoto,et al.  Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique. , 2008, Chemical & pharmaceutical bulletin.

[5]  Ayman Yahia Waddad,et al.  Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. , 2012, Die Pharmazie.

[6]  P. Kidd.  Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. , 2009, Alternative medicine review : a journal of clinical therapeutic.

[7]  F. Marmottini,et al.  Use of SBA-15 for furosemide oral delivery enhancement. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  E. Rogalska,et al.  Preparation of meloxicam–β-cyclodextrin–polyethylene glycol 6000 ternary system: characterization, in vitro and in vivo bioavailability , 2012, Pharmaceutical development and technology.

[10]  Patrick Augustijns,et al.  Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  M. Rao,et al.  Nanocrystallization by Evaporative Antisolvent Technique for Solubility and Bioavailability Enhancement of Telmisartan , 2012, AAPS PharmSciTech.

[12]  F. Veiga,et al.  Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine. , 2007, Journal of pharmaceutical sciences.

[13]  Deepak Bahl,et al.  Amorphization of Indomethacin by Co-Grinding with Neusilin US2: Amorphization Kinetics, Physical Stability and Mechanism , 2006, Pharmaceutical Research.

[14]  G. Belcaro,et al.  Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. , 2010, Alternative medicine review : a journal of clinical therapeutic.

[15]  Patrick Augustijns,et al.  Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[17]  M. Ramesh,et al.  Bioavailability Enhancement of Poorly Water Soluble and Weakly Acidic New Chemical Entity with 2-Hydroxy Propyl-β-Cyclodextrin: Selection of Meglumine, a Polyhydroxy Base, as a Novel Ternary Component , 2006, Pharmaceutical development and technology.

[18]  R. Bogner,et al.  Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 1: thermodynamics of spontaneous amorphization. , 2011, Journal of pharmaceutical sciences.

[19]  G. Belcaro,et al.  Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. , 2010, Panminerva medica.

[20]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[21]  Dimitrios N Bikiaris,et al.  Solid dispersions, Part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs , 2011, Expert opinion on drug delivery.

[22]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[23]  Sandip S Chavhan,et al.  Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study , 2011, Scientia pharmaceutica.

[24]  R. Manavalan,et al.  Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. , 2007, Die Pharmazie.

[25]  F. Bounoure,et al.  Solubility and Dissolution Rate of Progesterone-Cyclodextrin-Polymer Systems , 2006, Drug development and industrial pharmacy.

[26]  J. Foidart,et al.  Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Morton B. Brown,et al.  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.

[28]  Karthik Nagapudi,et al.  Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin. , 2011, Journal of pharmaceutical sciences.

[29]  Michael Levin.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[30]  Jinming Gao,et al.  Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.

[31]  L. Delattre,et al.  Oral bioavailability in pigs of a miconazole/Hydroxypropyl-γ-cyclodextrin/ L-tataric acid inclusion complex produced by supercritical carbon dioxide processing , 2005, The AAPS Journal.

[32]  R. Bogner,et al.  Formation of physically stable amorphous drugs by milling with Neusilin. , 2003, Journal of pharmaceutical sciences.

[33]  Wei Liu,et al.  Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. , 2012, Toxicology and applied pharmacology.

[34]  Yahya E Choonara,et al.  Diverse approaches for the enhancement of oral drug bioavailability , 2011, Biopharmaceutics & drug disposition.

[35]  Thorsteinn Loftsson,et al.  Cyclodextrins as pharmaceutical solubilizers. , 2007, Advanced drug delivery reviews.

[36]  Thomas Rades,et al.  Emerging trends in the stabilization of amorphous drugs. , 2013, International journal of pharmaceutics.

[37]  Hassan Benameur,et al.  Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. , 2008, Advanced drug delivery reviews.

[38]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.

[39]  Keith P. Johnston,et al.  Rapid dissolution of high-potency danazol particles produced by evaporative precipitation into aqueous solution. , 2004 .

[40]  F. Hirayama,et al.  Cyclodextrin-based controlled drug release system. , 1999, Advanced drug delivery reviews.

[41]  A. Y. Lu,et al.  Role of pharmacokinetics and metabolism in drug discovery and development. , 1997, Pharmacological reviews.

[42]  M. Schubert-Zsilavecz,et al.  Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome(®)) of Boswellia extract. , 2013, Fitoterapia.

[43]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[44]  N. Ganesh,et al.  Effect of dissolution rate by liquisolid compact approach: An overview , 2011 .

[45]  Qiang Zhang,et al.  Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. , 2012, Molecular pharmaceutics.

[46]  A. Gescher,et al.  Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine , 2007, Cancer Chemotherapy and Pharmacology.

[47]  K. Johnston,et al.  Supersaturation Produces High Bioavailability of Amorphous Danazol Particles Formed by Evaporative Precipitation into Aqueous Solution and Spray Freezing into Liquid Technologies , 2006, Drug development and industrial pharmacy.

[48]  P Amsa,et al.  Nanosuspensions: A Promising Drug Delivery Strategy , 2010 .

[49]  Rainer H Müller,et al.  Nanocrystal technology, drug delivery and clinical applications , 2008, International journal of nanomedicine.

[50]  R. Müller,et al.  Development of curcumin nanocrystal: physical aspects. , 2013, Journal of pharmaceutical sciences.

[51]  Y. Asiri,et al.  In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs. , 2001, International journal of pharmaceutics.

[52]  Dimitrios N Bikiaris,et al.  Solid dispersions, Part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs , 2011, Expert opinion on drug delivery.

[53]  P. Toutain,et al.  Bioavailability and its assessment. , 2004, Journal of veterinary pharmacology and therapeutics.

[54]  P. Kidd,et al.  A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). , 2005, Alternative medicine review : a journal of clinical therapeutic.

[55]  J. Dressman,et al.  Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine , 2004, The Journal of pharmacy and pharmacology.

[56]  Mo Li,et al.  Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs , 2009 .

[57]  G. Van den Mooter,et al.  Review: physical chemistry of solid dispersions , 2009 .

[58]  김태현.  Baxter International Inc. , 1998, Corporate Philanthropy Report.

[59]  Ranjita Shegokar,et al.  Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.

[60]  Xinsheng Peng,et al.  In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation , 2012, International journal of nanomedicine.

[61]  J. Dressman,et al.  New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  A. Millqvist-Fureby,et al.  Surface composition and contact angle relationships for differently prepared solid dispersions. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[63]  Zhouhua Wang,et al.  Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica , 2012, International journal of nanomedicine.

[64]  Huaxu Zhu,et al.  Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials. , 2012, Journal of Nanoscience and Nanotechnology.

[65]  N. Özdemir,et al.  Enhancement of dissolution rate and bioavailability of sulfamethoxazole by complexation with β-cyclodextrin , 2012, Drug development and industrial pharmacy.

[66]  C. Gardana,et al.  Relationship between rate and extent of catechin absorption and plasma antioxidant status , 1998, Biochemistry and molecular biology international.

[67]  アンドレア ジオーリ,et al.  Phospholipid complexes of curcumin having improved bioavailability , 2007 .

[68]  B. El-Houssieny,et al.  Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. , 2010, Bioscience trends.

[69]  Yanyu Xiao,et al.  Preparation and properties of a silybin-phospholipid complex. , 2008, Die Pharmazie.

[70]  P. Sylvester,et al.  Enhancement of Intestinal Permeability Utilizing Solid Lipid Nanoparticles Increases γ-Tocotrienol Oral Bioavailability , 2012, Lipids.

[71]  Caragh S Murphy,et al.  Optimization of a Dual Mechanism Gastrofloatable and Gastroadhesive Delivery System for Narrow Absorption Window Drugs , 2011, AAPS PharmSciTech.

[72]  K. Johnston,et al.  Cryogenic liquids, nanoparticles, and microencapsulation. , 2006, International journal of pharmaceutics.

[73]  R. Bogner,et al.  Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers. , 2009, Journal of pharmaceutical sciences.

[74]  R. N. Gürsoy,et al.  Nanocrystal Technology For Oral Delivery of Poorly Water-Soluble Drugs , 2011 .

[75]  F. Hirayama,et al.  Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin , 2000, Pharmaceutical development and technology.

[76]  R. Müller,et al.  Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation. , 2011, International journal of pharmaceutics.

[77]  H. Wikström,et al.  Understanding the Tendency of Amorphous Solid Dispersions to Undergo Amorphous–Amorphous Phase Separation in the Presence of Absorbed Moisture , 2011, AAPS PharmSciTech.

[78]  M. Semalty,et al.  Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. , 2010, Fitoterapia.

[79]  T. Loftsson.  Pharmaceutical applications of β-cyclodextrin , 1999 .

[80]  G. Amidon,et al.  Stability of valacyclovir: implications for its oral bioavailability. , 2006, International journal of pharmaceutics.

[81]  M. Alam,et al.  Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates , 2012, Expert opinion on drug delivery.

[82]  Qiang Zhang,et al.  pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[83]  Y. Krishnaiah.  Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs , 2010 .

[84]  A·焦里,et al.  Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability , 2007 .

[85]  J. Parikh,et al.  Preparation and Characterization of Co-Grinded Mixtures of Aceclofenac and Neusilin US2 for Dissolution Enhancement of Aceclofenac , 2009, AAPS PharmSciTech.

[86]  Elaine Merisko-Liversidge,et al.  Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.

[87]  Sang-Chul Shin,et al.  Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin , 2011, Archives of pharmacal research.

[88]  C. Harley,et al.  In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. , 2010, Drug metabolism and pharmacokinetics.

[89]  S. Gattani,et al.  Solubility Enhancement of Lovastatin by Modified Locust Bean Gum Using Solid Dispersion Techniques , 2008, AAPS PharmSciTech.

[90]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.